Minoryx Therapeutics sl - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Minoryx Therapeutics sl - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH451087D
  • |
  • Pages: 34
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Minoryx Therapeutics sl (Minoryx) is a clinical stage biotechnology company that develops treatments for life threatening rare diseases. The company offers discovery, preclinical research, development and clinical trial programs. It develops ALD-MIN, morquio B and PCT drugs used for lysosomal storage disorders and inherited peroxisomal neurodegenerative disorders. Minoryx also develops new class of compounds and non-competitive pharmacological chaperones that are identified through its innovative proprietary platform. The company offers pharmacological chaperone technology that provides class of small molecule drugs that stabilize unstable proteins. It provides solutions for treatment of genetic diseases severely affecting the central nervous system. The company operates in Mataro and Barcelona, Spain. Minoryx is headquartered in Mataro, Spain.

Minoryx Therapeutics sl-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Minoryx Therapeutics sl, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Minoryx Therapeutics sl, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Minoryx Therapeutics sl, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Minoryx Therapeutics sl, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Minoryx Therapeutics sl, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Minoryx Therapeutics sl, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Minoryx Therapeutics Raises USD25 Million in Series B Financing 11

Minoryx Therapeutics Raises USD22 Million in Series A Financing Round 13

Minoryx Therapeutics Raises Additional USD0.8 Million in Seed Financing 15

Minoryx Therapeutics Raises USD 2 Million In First Round Of Financing 16

Licensing Agreements 17

Minoryx Therapeutics Enters Into Licensing Agreement with Universitat de Barcelona and Institut de Investigacio Biomedica de Bellvitge 17

Minoryx Therapeutics Enters into Licensing Agreement with Bellvittge Biomedical 18

University of Barcelona And ICREA Enter Into Licensing Agreement With Minoryx 19

Equity Offering 20

Gain Therapeutics Spin Out from Minoryx Therapeutics 20

Minoryx Therapeutics sl-Key Competitors 21

Minoryx Therapeutics sl-Key Employees 22

Minoryx Therapeutics sl-Locations And Subsidiaries 23

Head Office 23

Recent Developments 24

Corporate Communications 24

Feb 08, 2017: Dr Claude Nicaise joins Minoryx Therapeutics as independent board member 24

Jan 18, 2017: Minoryx Therapeutics further strengthens its Scientific Advisory Board (SAB) 25

Product News 27

09/05/2018: Minoryx Therapeutics announces dosing of first US patient in phase 2/3 clinical study of MIN-102 (ADVANCE) 27

01/18/2017: Minoryx Therapeutics further strengthens its Scientific Advisory Board (SAB) 28

01/04/2018: Minoryx Therapeutics Announces The Dosing Of First Patient In Advance, A Phase 2/3 Clinical Study Of Min-102 In Patients With Adrenomyeloneuropathy (Amn) 30

Product Approvals 32

Feb 22, 2017: Minoryx Therapeutics receives Orphan Drug Designation from the US FDA for its lead candidate MIN-102 32

Clinical Trials 33

Mar 21, 2017: Minoryx Therapeutics successfully completes phase 1 clinical trial for lead candidate MIN-102 33

Appendix 34

Methodology 34

About GlobalData 34

Contact Us 34

Disclaimer 34

List of Figures

Minoryx Therapeutics sl, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Minoryx Therapeutics sl, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Minoryx Therapeutics sl, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Minoryx Therapeutics sl, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Minoryx Therapeutics sl, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Minoryx Therapeutics sl, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Minoryx Therapeutics sl, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Minoryx Therapeutics sl, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

List of Tables

Minoryx Therapeutics sl, Pharmaceuticals & Healthcare, Key Facts 2

Minoryx Therapeutics sl, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Minoryx Therapeutics sl, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Minoryx Therapeutics sl, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Minoryx Therapeutics sl, Deals By Therapy Area, 2012 to YTD 2018 8

Minoryx Therapeutics sl, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Minoryx Therapeutics Raises USD25 Million in Series B Financing 11

Minoryx Therapeutics Raises USD22 Million in Series A Financing Round 13

Minoryx Therapeutics Raises Additional USD0.8 Million in Seed Financing 15

Minoryx Therapeutics Raises USD 2 Million In First Round Of Financing 16

Minoryx Therapeutics Enters Into Licensing Agreement with Universitat de Barcelona and Institut de Investigacio Biomedica de Bellvitge 17

Minoryx Therapeutics Enters into Licensing Agreement with Bellvittge Biomedical 18

University of Barcelona And ICREA Enter Into Licensing Agreement With Minoryx 19

Gain Therapeutics Spin Out from Minoryx Therapeutics 20

Minoryx Therapeutics sl, Key Competitors 21

Minoryx Therapeutics sl, Key Employees 22

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Minoryx Therapeutics sl, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17835
Site License
USD 500 INR 35670
Corporate User License
USD 750 INR 53505

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com